MangoRush is a natural mango-flavored energy shot (30mL) manufactured in Honduras and currently selling in supermarkets and pharmacies across Latin America. Founded in 2026 by a family team with a combined 95 years of chemistry, pharmacology, and marketing experience, the brand has moved ~250,000 shots in its first two months with accelerating weekly velocity; 24 shots/store/week in December, 50 in January, 84 in February, and a >90% reorder rate from existing accounts.
https://www.mangorushenergia.com
The Product:
MangoRush is a 30mL energy shot with a clean, natural formulation: 150mg green tea caffeine extract, 100mg mango terpenes, 750mg taurine, and 100mg Vitamin B1. No synthetic caffeine, no artificial colors or flavors, no added sugar. Proprietary formulation patent pending. Third-party COA available.
P.S. Product design will be updated for the US market.
Unit Economics:
MSRP: $1.50/shot | $14.99/display box (12 shots)
Wholesale: $0.70/shot | $8.40/box
COGS (landed): $0.50/shot
Gross margin: 30%
Production capacity: up to 60,000 display boxes/month
MOQ full load: 25,920 displays (landed price under $0.50/shot)
Packaging: HDPE 30mL with UPC codes registered at unit, display, and master case level
Traction:
~250,000 shots sold in first 2 months in 2026
Active accounts (Honduras/Central America only at this moment): SuperZito, Siman, Kielsa, Farmacias Ahorro, Supercoop
Distribution: direct to retailer (grocery + pharmacy)
2026 revenue forecast: $1.5M–$1.8M
90% reorder rate from existing retail accounts
6-Month Distribution Targets:
Publix, Kroger, Costco; currently in initial talks stage with slotting fees budgeted.
The Raise — $9M Series A:
Investment Structure — $9M Series A | 4-Tranche Waterfall
Tranche 1 — Founding Investor | First $500K
Best terms available. Reserved for earliest capital committed.
Pre-money valuation: $15,000,000
Equity issued: ~3.3% per $500K
Investor advantage: 2x the equity of later tranches for same dollar in
Tranche 2 — Early Investor | Next $1,000,000
Pre-money valuation: $20,000,000
Equity issued: ~5.0% per $1M
Still significantly better than institutional tranches
Tranche 3 — Growth Investor | Next $3,000,000
Pre-money valuation: $25,000,000
Equity issued: ~12.0% per $3M
Standard early Series A terms
Tranche 4 — Series A Close | Final $4,500,000
Pre-money valuation: $30,000,000
Equity issued: ~15.0% per $4.5M
Headline valuation — least favorable equity per dollar invested
Total Round: $9,000,000 | Post-Money Valuation: ~$39,000,000
Investment Structure — $9M Series A | 4-Tranche Waterfall
Tranche 1 (Founding Investor — first $500K) offers the best terms in the round, with a $15M pre-money valuation giving investors approximately 3.3% equity at a cost of $150K per percentage point.
Tranche 2 (Early Investor — next $1M) steps up to a $20M pre-money valuation, delivering approximately 5.0% equity at $200K per percentage point — still significantly better than the later tranches.
Tranche 3 (Growth Investor — next $3M) is priced at a $25M pre-money valuation, representing approximately 12.0% equity at $250K per percentage point — standard early Series A terms.
Tranche 4 (Series A Close — final $4.5M) closes the round at the headline $30M pre-money valuation, issuing approximately 15.0% equity at $300K per percentage point — the least favorable equity per dollar invested.
Total round: $9,000,000. Post-money valuation: approximately $39,000,000. Founding investors acquire equity at exactly half the cost of close investors; first committed, best served.
Total founders' capital in: $500,000
Use of proceeds: Inventory/new facility (30%), Sales & marketing/trade spend (30%), Slotting fees & demos (10%), Working capital (10%), Distribution & logistics (5%), Legal/regulatory (5%), R&D (5%), Other (5%)
Returns to Investors:
Equity appreciation at exit (M&A / strategic acquisition) plus dividends. Profitability projected within 12–24 months. No future fundraising required to achieve stated projections.
Team:
Jorge Mendoza — Founder/CEO, Organic Chemist, 50 years experience
Jorge A. Mendoza — Chemical Engineer / Pharmacist, 30 years experience
Kenly Mendoza — Marketing Specialist, 15 years experience
Nicolas García — Key Account Manager (introduced aloe beverage to local market)
Dulce Nuñez — Chemical Engineer / Production Supervisor
Why MangoRush Wins:
Against Red Bull, 5-hour Energy, Celsius, and Monster — better taste, lower price, no jitters, one-gulp format. Broad appeal including female consumers who avoid large-format cans. Proprietary formulation, in-house research lab for rapid reformulation if needed, and a manufacturing moat with owned facility scaling to 500K–1M display boxes/month post-investment.
The better-for-you beverage market is one of the most active acquisition categories in CPG right now. Consumer products companies that reach $5M in revenue carry a 42% probability of achieving a liquidity event within five years, higher than B2B SaaS at similar revenue levels, and CPG exits happen faster and more frequently than tech. Real-world comparables bear this out: a functional beverage brand was acquired at $12M revenue for $36M in just 34 months from its angel round, and an organic snack brand exited at $32M on $8M in revenue in 28 months. Strategic buyers are now moving downstream, with acquisitions actively happening below $75M in revenue, and Food & Beverage M&A multiples currently sit at 10–11x EBITDA with EV/Revenue at approximately 1.5x across the broader market; a floor, not a ceiling, for a high-growth brand with proven velocity and a defensible price-point moat. MangoRush, with 250,000 shots sold in its first two months, accelerating weekly velocity, a >90% reorder rate, and a clear path to Publix, Kroger, and Costco, sits directly in the acquisition sweet spot that Monster, Red Bull, PepsiCo, and private equity roll-up platforms are actively targeting right now.
Related reading:
State of VC in CPG: 'Marquee Acquisitions' Kick Off Q1 2025 — https://www.bakeryandsnacks.com/Article/2025/03/12/cpg-ma-activity-set-to-rebound-vc-investments/
Food, Beverage & Agriculture M&A Trends & Multiples — https://mergersandacquisitions.net/insights/food-beverage-mergers-and-acquisitions
Consumer CPG Angel Funding: 2026 Deal Structures — https://angelinvestorsnetwork.com/angel-investing/consumer-cpg-angel-funding-why-2026-deals-structure-differently
This listing is for informational purposes only. All investments involve risk including loss of principal. Accredited investors only. Transactions occur solely on issuer-operated platforms.
